Search

Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.

The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).

• News
• Retinitis pigmentosa

During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.

• Webinar

Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.

• News
• Retinitis pigmentosa

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.

• News
• Retinitis pigmentosa

This edition of Look Forward is packed full of details of our plans for 2022. There is so much going on and being able to get together in person is a big part of that.

• Look Forward
• Audio
• Written

The following questions are often asked by people contacting Retina UK.

A recording of the 46th Retina UK Annual Conference on 24 June 2023. The Conference was held at the University of Westminster, Marylebone Campus in London and online.

• Conference
• Audio
• Video

The Great North Run is the largest half marathon in the world, taking place annually in Newcastle.

• Run
• Newcastle